Three days after citing “bottom-line set-backs and expense creep” for a 5 percent reduction in Bruker BioSciences’ workforce, CEO Frank Laukien said on Monday that the company is filling a backlog of orders that missed “getting out the door”— turning into revenues — in the second quarter.

“And that bodes well for the future,” Laukien told analysts and investors at the Bear Stearns Healthcare Conference in New York.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.